Drug Trial Radar · NCT00158691
Intravenous Versus Subcutaneous Amifostine in Prevention of Xerostomia After RT for Head and Neck Carcinomas
Last checked: Nov 20, 2026Latest source record: Sep 12, 2005 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
296
Actual
Start
Mar 2001
Primary completion
Not stated
Sponsor
- Lead sponsor
- Groupe Oncologie Radiotherapie Tete et CouAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Schering-Plough
- First posted
- Sep 12, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
Summary
As written by the sponsor on the registry.
Prospective randomized study in order to compare intravenous versus subcutaneous administration of amifostine in patients receiving radiotherapy for head and neck cancer. Salivary flow will be evaluated during few years after the treatment by a clinical evaluation, the measure of the weight of saliva and a patient benefit questionnaire cotation.
Conditions
- Head and Neck Cancer
Interventions
EthyolDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Late xerostomia rate
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Centre Régional de Lutte contre le Cancer de Nantes-Atlantique
Nantes, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.